290 patents
Page 4 of 15
Utility
Glucosylceramide Synthase Inhibitors
29 Dec 22
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy.
John P. LEONARD, Jean-François DELEUZE, Jean-Michel ITIER, Cécile ORSINI, Gwénaëlle RET-LECUELLE, Sandra VIALE
Filed: 25 May 22
Utility
Biparatopic CD73 Antibodies
22 Dec 22
Anti-CD73 antigen-binding proteins are provided.
Dana LORD, Katarina RADOSEVIC, James E. STEFANO, Yenfang ZHOU
Filed: 13 Nov 20
Utility
Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors
20 Dec 22
John L. Kane, Jr., Nellwyn A. Hagan, Maria A. Fitzgerald
Filed: 11 Feb 22
Utility
Enhanced Delivery of Viral Particles to the Striatum and Cortex
15 Dec 22
Provided herein are novel methods for delivering recombinant adeno-associated viral (rAAV) particles to the central nervous system of a mammal (e.g., a human).
Lisa M. STANEK, Lamya S. SHIHABUDDIN
Filed: 29 Jul 22
Utility
Colony Stimulating FACTOR-1 Receptor (CSF-1R) Inhibitors
15 Dec 22
John L. Kane, JR., Claude Barberis, Mark Czekaj, Paul Erdman, Barret Giese, Michael Kothe, Tieu-Binh Le, Jinyu Liu, Liang Ma, Markus Metz, Vinod Patel, Andrew Scholte, Patrick Shum, Linli Wei
Filed: 9 Feb 22
Utility
Composition and Methods for Sanitization
24 Nov 22
The present technology relates to a novel sanitization method for chromatography media and supporting equipment comprising treatment with a sanitization/sterilization solution comprising acetic acid and hexylene glycol.
Joseph P. Kutzko, Ryan F. Wollensak
Filed: 6 May 22
Utility
Slow Intraventricular Delivery
24 Nov 22
Neurological diseases, including lysosomal storage diseases, can be successfully treated using intraventricular delivery of the therapeutic agents to bypass the blood-brain barrier.
James C. DODGE, Marco A. PASSINI, Lamya S. SHIHABUDDIN, Seng H. CHENG
Filed: 10 Jan 22
Utility
Tangential viral filtration
22 Nov 22
Viral filters include a filter member featuring a first surface and a second surface and having a thickness extending between the first and second surfaces in a first direction, and a plurality of channels formed in the filter member, each of the channels having a channel axis, where during use, a solution carrying a viral load flows in a direction parallel to the first surface, and at least a portion of the viral load enters the membrane through the first surface and propagates in the first direction, and where for at least 50% of the channels in the filter member, the channel axis is oriented at an angle of between 5 degrees and 85 degrees relative to the first direction.
Tarl Vetter, Kevin Brower
Filed: 11 Mar 20
Utility
FGFR3 antibodies and methods of use
22 Nov 22
Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided.
Yves Sabbagh, Yangde Chen, William Brondyk, Huawei Qiu, Sunghae Park, Ronnie Wei, Yu Qiu, Yanfeng Zhou, Cendrine Lemoine, HyunSuk Cho
Filed: 20 Aug 21
Utility
SCFV-FC Dimers That Bind Transforming Growth FACTOR-BETA1 with High Affinity, Avidity and Specificity
17 Nov 22
An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity.
Huawei Qiu, Clark Pan, Julie Bird
Filed: 4 Apr 22
Utility
Methods for Producing Preparations of Recombinant Aav Virions Substantially Free of Empty Capsids
17 Nov 22
Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described.
Guang QU, John Fraser WRIGHT
Filed: 19 Jan 22
Utility
USE OF iNOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTURE
27 Oct 22
The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.
Peter PECHAN, Jeffery ARDINGER, Abraham SCARIA, Samuel WADSWORTH
Filed: 3 Mar 22
Utility
Methods of Perfusion Culturing a Mammalian Cell
20 Oct 22
Provided herein are methods of perfusion culturing a mammalian cell that include: providing a vessel containing a mammalian cell disposed in a first liquid culture medium having an osmolality of about 270 mOsm/kg to about 380 mOsm/kg; incubating the mammalian cell for a period of time at about 32° C. to about 39° C.; and during the period of time, continuously or periodically removing a first volume of the first liquid culture medium and adding to the first liquid culture medium a second volume of a second liquid culture medium, wherein the first and second volumes are about equal and the osmolality of the first and second liquid culture medium in the vessel is maintained at about 270 mOsm/kg to about 380 mOsm/kg over the period of time.
Shawn L. Barrett, Charles Budde, Daryl Powers
Filed: 14 Apr 22
Utility
MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY
6 Oct 22
A modified IgG antibody binds and neutralizes TGFβ1 selectively and with high affinity and avidity.
Huawei Qiu, Julie Bird
Filed: 11 Apr 22
Utility
Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
4 Oct 22
Hanlan Liu, Chris Willis, Renu Bhardwaj, Jianmei Kochling, Craig Siegel
Filed: 24 Nov 10
Utility
Dose Escalation Enzyme Replacement Therapy for Treating Acid Sphingomyelinase Deficiency
29 Sep 22
The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
Edward H. Schuchman, Robert J. Desnick, Gerald F. Cox, Laura P. Andrews, James M. Murray
Filed: 18 Feb 22
Utility
Methods for Improving Cell Viability In A Production BioReactor
29 Sep 22
Provided herein are methods of predicting the effect of a concentration of a sensitizer on cell viability in a production bioreactor, methods of improving cell viability in a production bioreactor, methods of predicting cell viability in a production bioreactor, and methods for culturing a cell in a production bioreactor.
Jonathan Wang, Neha Shah, Jason Walther, Jiuyi Lu, Timothy Johnson, Yukun Ren, Jean McLarty
Filed: 16 Jun 22
Utility
Compositions and Methods for Treating and Preventing Macular Degeneration
15 Sep 22
Compositions and methods for treating macular degeneration are disclosed.
Abraham SCARIA
Filed: 25 Feb 22
Utility
Tangential viral filtration
13 Sep 22
Viral filters include a filter member featuring a first surface and a second surface and having a thickness extending between the first and second surfaces in a first direction, and a plurality of channels formed in the filter member, each of the channels having a channel axis, where during use, a solution carrying a viral load flows in a direction parallel to the first surface, and at least a portion of the viral load enters the membrane through the first surface and propagates in the first direction, and where for at least 50% of the channels in the filter member, the channel axis is oriented at an angle of between 5 degrees and 85 degrees relative to the first direction.
Tarl Vetter, Kevin Brower
Filed: 7 Dec 21
Utility
Perfusion bioreactor with filtration systems
6 Sep 22
The disclosure provides a filtration system for a cell culture apparatus and a method of cell culture.
Jiuyi Lu, Jason Walther, Jonathan Wang, Kevin Victor Chen
Filed: 11 Nov 21